Diagens-B Stock Nearly Doubles in Pre-Listing Trade

Edgen Stock

·Mar 27 2026, 09:03

Share to

Share to

Copy link

Key Takeaways

Shares of biotechnology firm Diagens-B (02526.HK) showed exceptional investor demand ahead of its official Hong Kong listing, surging dramatically in grey market trading. The performance signals strong positive sentiment for the company's public debut.

Diagens-B stock price soared as high as 99.1% above its listing price on the grey market.
The stock is scheduled to be officially listed on the Hong Kong Stock Exchange on March 30.
Combined trading turnover across two major platforms exceeded $87 million, indicating robust pre-IPO investor interest.

Diagens-B Surges Over 99% Ahead of Listing

Shares of biotechnology firm Diagens-B (02526.HK) experienced a powerful run in grey market trading, nearly doubling in value before its official market debut scheduled for March 30. According to data from the Futu platform, the stock opened at $150, a 51.5% premium to its listing price, and ultimately closed at $197, a gain of 99%. Performance was similarly strong on the PhillipMart platform, where shares opened at $140, up 41.4%, and ended the session at $197.1, reflecting a 99.1% increase.

Investor Demand Drives Turnover Above $87 Million

The sharp price appreciation was fueled by significant trading volume, signaling strong investor appetite for the upcoming IPO. The combined turnover from the Futu and PhillipMart platforms totaled approximately $87.6 million. Futu registered a turnover of $55 million from 296,350 shares traded, while PhillipMart saw a turnover of $32.6 million on a volume of 182,000 shares. This high level of activity points to a bullish reception as the stock prepares for its formal introduction to the public market.